Literature DB >> 11581298

Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.

J Lam1, C A Nelson, F P Ross, S L Teitelbaum, D H Fremont.   

Abstract

RANK, the receptor activator of NF-kappaB, and its ligand RANKL (initially termed TRANCE, also termed ODF and OPGL), are a TNF superfamily receptor-ligand pair that govern the development and function of osteoclasts, lymphoid tissue, and mammary epithelium. While TNF family cytokines share a common structural scaffold, individual receptor-ligand pairs associate with high specificity. Given the low level of amino acid conservation among members of the TNF superfamily, the means by which these molecules achieve specificity cannot be completely understood without knowledge of their three-dimensional structures. To determine the elements of RANKL that mediate RANK activation, we have crystallized the ectodomain of murine RANKL and solved its structure to a resolution of 2.6 A. RANKL self-associates as a homotrimer with four unique surface loops that distinguish it from other TNF family cytokines. Mutagenesis of selected residues in these loops significantly modulates RANK activation, as evidenced by in vitro osteoclastogenesis, thereby establishing their necessity in mediating the biological activities of RANKL. Such structural determinants of RANKL-RANK specificity may be of relevance in the pharmacologic design of compounds to ameliorate osteopenic disorders of bone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581298      PMCID: PMC200957          DOI: 10.1172/JCI13890

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

Authors:  A Truneh; S Sharma; C Silverman; S Khandekar; M P Reddy; K C Deen; M M McLaughlin; S M Srinivasula; G P Livi; L A Marshall; E S Alnemri; W V Williams; M L Doyle
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

Review 2.  The tumour necrosis factor receptor family: life or death choices.

Authors:  E Y Jones
Journal:  Curr Opin Struct Biol       Date:  2000-12       Impact factor: 6.809

3.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.

Authors:  S Cenci; M N Weitzmann; C Roggia; N Namba; D Novack; J Woodring; R Pacifici
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

4.  Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity.

Authors:  S S Cha; B J Sung; Y A Kim; Y L Song; H J Kim; S Kim; M S Lee; B H Oh
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

5.  Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection.

Authors:  Y T Teng; H Nguyen; X Gao; Y Y Kong; R M Gorczynski; B Singh; R P Ellen; J M Penninger
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

6.  The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.

Authors:  J E Fata; Y Y Kong; J Li; T Sasaki; J Irie-Sasaki; R A Moorehead; R Elliott; S Scully; E B Voura; D L Lacey; W J Boyle; R Khokha; J M Penninger
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

7.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

Authors:  J Li; I Sarosi; X Q Yan; S Morony; C Capparelli; H L Tan; S McCabe; R Elliott; S Scully; G Van; S Kaufman; S C Juan; Y Sun; J Tarpley; L Martin; K Christensen; J McCabe; P Kostenuik; H Hsu; F Fletcher; C R Dunstan; D L Lacey; W J Boyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

8.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.

Authors:  J Lam; S Takeshita; J E Barker; O Kanagawa; F P Ross; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

9.  Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain.

Authors:  D Willard; W J Chen; G Barrett; K Blackburn; J Bynum; T Consler; C Hoffman; E Horne; M A Iannone; S Kadwell; J Parham; B Ellis
Journal:  Protein Expr Purif       Date:  2000-10       Impact factor: 1.650

10.  Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE.

Authors:  D Kim; R E Mebius; J D MacMicking; S Jung; T Cupedo; Y Castellanos; J Rho; B R Wong; R Josien; N Kim; P D Rennert; Y Choi
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

View more
  57 in total

Review 1.  Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis.

Authors:  J Lam; Y Abu-Amer; C A Nelson; D H Fremont; F P Ross; S L Teitelbaum
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

3.  Mycobacterium tuberculosis chaperonin 10 heptamers self-associate through their biologically active loops.

Authors:  Michael M Roberts; Alun R Coker; Gianluca Fossati; Paolo Mascagni; Anthony R M Coates; Steve P Wood
Journal:  J Bacteriol       Date:  2003-07       Impact factor: 3.490

4.  RANKing c-Jun in osteoclast development.

Authors:  Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.

Authors:  Tadashi Mori; Akihiro Oguro; Takashi Ohtsu; Yoshikazu Nakamura
Journal:  Nucleic Acids Res       Date:  2004-11-23       Impact factor: 16.971

6.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

7.  Crystallization and preliminary X-ray analysis of mouse RANK and its complex with RANKL.

Authors:  Thomas S Walter; Changzhen Liu; Peng Huang; Shiqian Zhang; Lucy R Wedderburn; Bin Gao; Raymond J Owens; David I Stuart; Peifu Tang; Jingshan Ren
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-05-22

8.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

Review 9.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

Review 10.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.